Company: BOLT
Filing Date: 2025-01-03
Form Type: 8-K
Source: 0000950170-25-001159
Chunk: 1

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-01-03
Form: 8-K
Item: Item 3.01
Chunk 1
---
, 2025, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal Nasdaq’s delisting determination to a Nasdaq hearings panel. There can be no assurance that, if the Company does appeal any delisting determination by Nasdaq to the hearings panel, such appeal would be successful.

The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or maintain compliance with the other listing requirements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                           Bolt Biotherapeutics, Inc.                                      
  Date:      January 3, 2025      By:      /s/ William P. Quinn                                            
                                           William P. Quinn